Welcome to our dedicated page for Xencor SEC filings (Ticker: XNCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, royalty waterfalls, and collaboration milestones make Xencor filings some of the most intricate in biotech. If you have ever asked, “Where can I find the Xencor quarterly earnings report 10-Q filing?” or “How do I track Xencor insider trading Form 4 transactions before key readouts?”, you know the challenge: hundreds of pages packed with protein-engineering jargon and risk-factor cross-references.
Stock Titan solves that problem. Our AI reads every 10-K, 10-Q, 8-K and proxy statement the moment it hits EDGAR, then delivers concise explanations in plain English. Need the Xencor annual report 10-K simplified? One click reveals R&D spend by program, cash runway, and partnership revenue. Curious about pipeline progress disclosed in an 8-K? You’ll see Xencor 8-K material events explained in context—no legal dictionary required. And because biotech moves quickly, our real-time alerts surface Xencor Form 4 insider transactions real-time, letting you monitor executive stock transactions Form 4 alongside AI commentary on timing and size.
Whether you’re modeling future royalties or comparing quarter-over-quarter burn, our platform connects each filing type to the details that matter. The 10-Q module offers Xencor earnings report filing analysis with trend charts, while the proxy hub answers “How is stock-based pay structured in the Xencor proxy statement executive compensation section?” For investors who simply want Xencor SEC filings explained simply, the AI summary panel turns dense disclosures into clear takeaways, helping you make informed decisions without wading through technical appendices or footnotes.
Xencor reported Q3 results with revenue of $20,999 from collaborations, milestones and royalties, down the P&L to an operating loss of $47,519. A strong swing in other income, including $44,201 of gains on marketable equity securities, narrowed the quarter’s net loss to $6,027.
Year to date, revenue reached $97,339, aided by Incyte milestones of $12,500 and $25,000 triggered by U.S. regulatory events. Research and development expense was $54,367 in Q3, and the company recorded asset impairment charges of $1,565 tied to pausing certain programs. Liquidity comprised cash and cash equivalents of $28,291, marketable debt securities of $358,493 current and $247,158 long term, and marketable equity securities of $84,260. Liabilities related to prior royalty sales declined to $133,138 after $55,037 of payments to OMERS. Net cash used in operating activities was $83,406 for the nine months. Shares outstanding were 71,410,469 as of October 30, 2025. The at‑the‑market facility remained unused, and pre‑funded warrants from September 2024 remain exercisable.
Xencor, Inc. furnished a Form 8-K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1.
The company stated this information is being furnished and shall not be deemed to be filed under the Exchange Act. The filing also includes the cover page interactive data file.
Xencor, Inc. furnished an update under Regulation FD. The company held a conference call on October 24, 2025 to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3), early data from the ongoing Phase 1 dose-escalation study of XmAb541 (CLDN6 x CD3), and associated near-term clinical timelines.
Supporting materials were furnished, not filed, including a presentation (Exhibit 99.1) and a press release (Exhibit 99.2). The presentation is stated to be current as of April 29, 2025. The company noted that these materials are incorporated by reference as furnished under Item 7.01 and are not deemed filed for Section 18 purposes.
Primecap Management reports beneficial ownership of 10,527,322 shares of Xencor common stock, representing 14.79% of the class. The filing states Primecap has sole voting power and sole dispositive power over these shares, with no shared voting or dispositive power reported.
The statement certifies the shares are held in the ordinary course of business and were not acquired to change or influence control of Xencor. The filing also identifies the PRIMECAP Odyssey Aggressive Growth Fund as having an interest exceeding 5% of Xencor's outstanding common stock.
Xencor, Inc. (XNCR) – Form 4 insider filing, dated 31 Jul 2025. Independent director Raymond J. Deshaies received a single equity award and reported no open-market purchases or sales.
- Transaction: One stock option granting the right to buy 110,422 common shares at an exercise price of $8.32.
- Vesting: 1⁄3 of the option (36,807 shares) vests on 31 Jul 2026; the remaining 73,615 shares vest in equal monthly installments over the next 24 months. Expiration: 31 Jul 2035.
- Post-transaction holdings: Deshaies now beneficially owns 110,422 derivative securities; no non-derivative share ownership was reported.
The filing reflects a routine director incentive grant with a 10-year life and service-based vesting. It does not involve immediate cash outflow by the insider, nor does it signal open-market sentiment. Potential dilution is minimal relative to Xencor’s ~60 million shares outstanding, but the award aligns the director’s interests with long-term shareholder value.
FAQ
What is the current stock price of Xencor (XNCR)?
What is the market cap of Xencor (XNCR)?
